[HTML][HTML] How to choose the right treatment for membranous nephropathy
L Peritore, V Labbozzetta, V Maressa, C Casuscelli… - Medicina, 2023 - mdpi.com
Membranous nephropathy is an autoimmune disease affecting the glomeruli and is one of
the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of …
the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of …
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a …
H Schrezenmeier, A Kulasekararaj… - Therapeutic …, 2020 - journals.sagepub.com
Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with
paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab …
paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab …
Advances in research on renal injury in paroxysmal nocturnal
L Li, R Fu - Journal of Investigative Medicine, 2024 - journals.sagepub.com
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell
disease. Clinical manifestations include intravascular hemolysis, renal dysfunction, fatigue …
disease. Clinical manifestations include intravascular hemolysis, renal dysfunction, fatigue …
[HTML][HTML] COVID19 infection in a patient with paroxysmal nocturnal hemoglobinuria: A case report
J Sokol, F Nehaj, M Mokan, L Lisa, J Stasko - Medicine, 2021 - journals.lww.com
Conclusion: The complement system activation is a critical component in the sequalae of
COVID19 infection. Evidence suggests that severe outcomes in COVID19 infection are …
COVID19 infection. Evidence suggests that severe outcomes in COVID19 infection are …
[HTML][HTML] Paroxysmal nocturnal hemoglobinuria
N Shah, H Bhatt - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
Paroxysmal Nocturnal Hemoglobinuria - StatPearls - NCBI Bookshelf US flag An official website
of the United States government Here's how you know NIH NLM Logo Access keys NCBI …
of the United States government Here's how you know NIH NLM Logo Access keys NCBI …
[HTML][HTML] Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
H Lee, J Park, H Jang, SJ Lee, J Kim - European Journal of Clinical …, 2024 - Springer
Purpose To describe, compare similarity of pharmacokinetic (PK), pharmacodynamic (PD)
and efficacy of SB12 and reference eculizumab (ECU) and find clinically significant …
and efficacy of SB12 and reference eculizumab (ECU) and find clinically significant …
[HTML][HTML] COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
S Shikdar, A Borogovac, E Mohamad… - Thrombosis …, 2021 - Springer
Background In the recent COVID19 pandemic, patients with hematological disorders were
considered at high risk for severe disease. Limited data is available regarding the course of …
considered at high risk for severe disease. Limited data is available regarding the course of …
The Clinical Case of Peripheral Artery Disease with Post-Thrombotic Disease in a Patient with Type 2 Diabetes Mellitus
MI Sheremet, SM Gramatiuk, IY Bagmut… - Romanian Journal of …, 2020 - rjdnmd.org
Background and aims: Mesenchymal stem cells have the capacity for multidirectional
differentiation and poor immunogenicity; these cells are widely used in the field of …
differentiation and poor immunogenicity; these cells are widely used in the field of …
Deficiencia de proteínas de superficie en el diagnóstico de hemoglobinuria paroxística nocturna
S Mena-Zapata - Salutem Scientia Spiritus, 2024 - revistas.javerianacali.edu.co
La hemoglobinuria paroxística nocturna es una enfermedad hematológica adquirida
causada por una mutación en el gen PIG-A, que codifica la proteína fosfatidilinositol glicano …
causada por una mutación en el gen PIG-A, que codifica la proteína fosfatidilinositol glicano …
Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria
F Begum, N Khan, S Boisclair… - American Journal of …, 2023 - journals.lww.com
Background: Complement-mediated HUS (CM-HUS) and paroxysmal nocturnal
hemoglobinuria (PNH) are rare hematologic disorders that cause dysregulation and …
hemoglobinuria (PNH) are rare hematologic disorders that cause dysregulation and …